抗纤维化策略和肺纤维化
Avanka Gunatilaka1, Stephanie Zhang2, Wan Shun Daniel Tan2
1Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, VIC, Australia; ARC Centre for Personalised Therapeutics Technologies, The University of Melbourne, Parkville, VIC, Australia.
Advances in pharmacology (San Diego, Calif.)
|July 31, 2023
概括
异常性肺纤维化 (IPF) 涉及由于异常修复导致的肺部痕. 需要更准确的模型来开发有效的抗纤维菌治疗方法,以阻止疾病的进展.
科学领域:
- 肺部医学 肺部医学
- 纤维化研究 纤维化研究
- 药物开发 药物开发
背景情况:
- 异形性肺纤维化 (IPF) 的特征是肺组织痕和硬化.
- IPF的确切原因和复杂的信号通路仍然不完全理解.
- 目前的治疗方法只能减缓IPF的进展,这凸显了对新型治疗策略的需求.
研究的目的:
- 解决当前临床前模型在准确表示IPF方面的局限性.
- 探索先进疾病模型的潜力,以更好地评估候选药物.
- 确定针对纤维生成途径和IPF中的细胞外微环境的改进策略.
主要方法:
- 审查IPF病原和现有实验模型的局限性的当前理解.
- 讨论先进的体外模型,如3D培养,有机体和精密切割肺切片 (PCLS).
- 分析针对纤维生成途径和细胞外微环境的抗纤维菌药物开发的最新进展.
主要成果:
- 现有的临床前模型不足以捕捉IPF的复杂性,包括细胞-细胞和细胞-矩阵相互作用.
- 像PCLS和有机体这样的先进模型提供了更准确的IPF病理生物学表示.
- 准纤维生成信号通路和细胞外微环境显示出对抗纤维菌治疗的前景.
结论:
- 更多与疾病相关的实验模型对于改善IPF候选药物的临床疗效预测至关重要.
- 开发能够阻止或逆转IPF进展的疗法需要更深入地了解其复杂的发病因子.
- 未来的研究应该专注于利用先进的模型,以更好地为肺纤维化治疗药物标提供资格.
相关概念视频
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
205
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
205
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K